Atossa Therapeutics (NASDAQ:ATOS) Rating Lowered to “Sell” at StockNews.com

Atossa Therapeutics (NASDAQ:ATOS) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

Other research analysts have also issued reports about the company. Ascendiant Capital Markets upped their price target on Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a report on Wednesday, September 11th. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Atossa Therapeutics in a research note on Thursday, October 31st.

Atossa Therapeutics Price Performance

Shares of ATOS opened at $1.50 on Friday. The company has a market capitalization of $188.64 million, a PE ratio of -7.14 and a beta of 1.23. Atossa Therapeutics has a one year low of $0.62 and a one year high of $2.31. The company’s fifty day moving average price is $1.44 and its 200 day moving average price is $1.38.

Atossa Therapeutics (NASDAQ:ATOS) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. Analysts anticipate that Atossa Therapeutics will post -0.22 earnings per share for the current year.

Hedge Funds Weigh In On Atossa Therapeutics

Large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in shares of Atossa Therapeutics during the 2nd quarter worth approximately $29,000. Intech Investment Management LLC acquired a new stake in Atossa Therapeutics during the third quarter worth $29,000. SG Americas Securities LLC increased its holdings in Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after buying an additional 30,037 shares during the period. Cetera Advisors LLC acquired a new position in shares of Atossa Therapeutics in the 1st quarter valued at $72,000. Finally, Virtu Financial LLC bought a new position in shares of Atossa Therapeutics during the 1st quarter worth about $151,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.